“Our large-scale, international, real-world analysis supports the absence of a clinical benefit of chloroquine and hydroxychloroquine and points to potential harm in hospitalised patients with COVID-19,” the study reads.
Hydroxychloroquine can prevent lupus flares and increase long-term survival of patients with the disease. Without it, however, lupus patients stand to endure more pain and suffering.
